<span item_type="fundamental" item_id="fb38efa251c5fb6a126dc5174f9ba213" counter_id="ST/US/GTHP" env="prod"></span><span item_type="announcement" item_id="516476270385108993" env="prod"></span><p>Revenue: As of FY2025 Q1, the actual value is USD 0.</p><p>EPS: As of FY2025 Q1, the actual value is USD -0.01.</p><p>EBIT: As of FY2025 Q1, the actual value is USD -427 K.</p><p></p><h3>Segment Revenue</h3><ul><li><strong>Sales - Devices and Disposables</strong>: Revenue for the three months ended March 31, 2025 was $0, compared to $6 for the same period in 2024.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/924515/000147793225003835/gthp_10q.htm"></span></li></ul><h3>Operational Metrics</h3><ul><li><strong>Net Loss</strong>: The net loss attributable to common stockholders was $462,742 for the three months ended March 31, 2025, compared to $441,372 for the same period in 2024.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/924515/000147793225003835/gthp_10q.htm"></span></li><li><strong>Operating Expenses</strong>: Total operating expenses were $414,000 for the three months ended March 31, 2025, compared to $363,000 for the same period in 2024.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/924515/000147793225003835/gthp_10q.htm"></span></li><li><strong>Interest Expense</strong>: Interest expense was $146,899 for the three months ended March 31, 2025, compared to $61,473 for the same period in 2024.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/924515/000147793225003835/gthp_10q.htm"></span></li></ul><h3>Cash Flow</h3><ul><li><strong>Net Cash Used in Operating Activities</strong>: Net cash used in operating activities was $331,000 for the three months ended March 31, 2025, compared to $100,000 for the same period in 2024.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/924515/000147793225003835/gthp_10q.htm"></span></li><li><strong>Net Cash Provided by Financing Activities</strong>: Net cash provided by financing activities was $58,000 for the three months ended March 31, 2025, compared to net cash used of $46,000 for the same period in 2024.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/924515/000147793225003835/gthp_10q.htm"></span></li></ul><h3>Unique Metrics</h3><ul><li><strong>Deferred Revenue</strong>: Deferred revenue totaled $670,305 as of March 31, 2025, compared to $848,917 as of December 31, 2024.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/924515/000147793225003835/gthp_10q.htm"></span></li></ul><h3>Future Outlook and Strategy</h3><ul><li><strong>Core Business Focus</strong>: The company is focused on the commercialization of its LuViva non-invasive cervical cancer detection device, with efforts to achieve regulatory approval in China and the United States. The company expects to generate approximately $2.0 million in sales within the next twelve months based on current purchase orders and agreements.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/924515/000147793225003835/gthp_10q.htm"></span></li><li><strong>Non-Core Business</strong>: The company is exploring international markets, including Turkey and Indonesia, where it has received sales orders and regulatory approvals, expected to result in approximately $500,000 in revenue for 2025.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/924515/000147793225003835/gthp_10q.htm"></span></li></ul>

Guided Therapeutics, Inc. | 10-Q: FY2025 Q1 Revenue: USD 0